HIV Vaccine R&D at R4P, a roadmap for busy people

The 4th HIV Research for Prevention Conference (HIVR4P // Virtual) will be take place on 27-28 January and 3-4 February 2021. The Enterprise has developed an HIV vaccines roadmap for those interested in following HIV vaccine updates in particular. This includes broadly neutralizing antibodies (bNAbs), especially VRC01.

A more comprehensive roadmap is also available as an Excel spreadsheet.

  • First responders, a symposia chaired by Keith Reeves (Center for Virology and Vaccine Research, United States and Caroline Tiemessen, National Institute for Communicable Diseases, South Africa) describing the initial innate immune response to vaccines, including adjuvants, and the link to adaptive immunity.
  • Achieving the unfulfilled promise of PMTCT, a symposia that includes a presentation by Lynda Stranix-Chibanda (University of Zimbabwe College of Health Sciences, Zimbabwe) on ‘Vaccine and antibody strategies to address the gap’.
  • HIV & TB: An R&D tale of two vaccines, a satellite organised by the Enterprise in partnership with the TB Vaccine Initiative (TBVI). More information about this event are available here.

bNAb-themed sessions:

  • Late breaking trials at R4P, a hybrid session chaired by Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom) which include the presentation of the AMP studies as well as interim results of the Long acting injectable cabotegravir for the prevention of HIV infection in cisgender women
  • Coming soon to a clinic near you? The antibody infusion pipeline, a roundtable chaired by Kundai Chinyenze, IAVI, Kenya and Andrew Mujugira, Makerere University, Uganda.
  • The clinical march of bNAbs, an oral abstract session including presentations on the ‘Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081)’ and ‘Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085)’.

bNAb-themed

  • Building better bNAbs, an oral abstract session chaired by Amy Chung (The Peter Doherty Institute for Infection and Immunity, Australia) and Marit van Gils (Academic Medical Center, Netherlands) including presentations on ‘Vaccination Induces Maturation of Diverse Unmutated VRC01-Class Precursors to HIV-1 Broadly Neutralizing Antibodies in an Ig-humanized Mouse Model’, ‘Development of a novel VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies’.
  • Getting the job done: Designing immunogens to induce broadly neutralizing antibodies, a symposium chaired by Max Crispin (University of Southampton, United Kingdom) and Tom Hanke (University of Oxford, United Kingdom).

NAb-themed session on 4 February:

Vaccine-themed abstracts:

  • Oral abstract ‘Early Vaccine-Induced V1V2 Antibody Responses in Four Pox-Protein Public Private Partnership (P5) HIV Vaccine Trials’ (Fatima Laher)
  • On-demand poster ‘Baseline host determinants of robust human HIV vaccine responses ‘ a meta-analysis of 26 vaccine regimens’ (Yunda Huang)
  • On-demand poster ‘High HIV incidence among women in the HVTN 702 vaccine trial with limited ability to elucidate drivers of HIV risk’ (Holly Janes)
  • E-poster ‘PrEP use in the HVTN 702 HIV vaccine efficacy trial conducted in South Africa’ (Jackline Odhiambo)
  • E-poster ‘HIV prevention research and development funding trends 2000’2019: investment priorities to fund innovation in a challenging global health landscape’ (Fatima Riaz)

bNAb-themed abstracts:

  • Oral abstract ‘Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081)’(Nonhlanhla N. Mkhize)
  • Oral abstract ‘Vaccination induces maturation of diverse unmutated VRC01-class precursors to HIV-1 broadly neutralizing antibodies in an Ig-humanized mouse model’ (Xuejun Chen)
  • Oral abstract ‘Analysis of genetic diversity and VRC01 pressure on HIV-1 breakthrough viruses from the AMP trial (HVTN 703/HPTN 081 and HVTN 704/085)’ (Carolyn Williamson)
  • E-poster ‘Improved potency, breadth, and pharmacokinetics of VRC01-class antibodies for HIV-1 prevention and treatment’ (Young Do Kwon)
  • Oral abstract ‘Development of a novel VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies’ (Emilie Seydoux)
The Enterprise is also sponsoring two live satellites.

Wednesday 27 January, 18:45 – 20:15 (UTC) channel 2

HIV & TB: An R&D tale of two vaccines, in partnership with the TuBerculosis Vaccine Initiative (TBVI).

The aim of the satellite is to examine lessons learned from our respective R&D journey and look to a future in which integrated research supports product development. Through two panel discussions and an audience Q&A, we will explore the role of the industry, how to develop mutually beneficial academic-industry relationships, as well as funding structures and mechanisms that create a sustainable R&D environment.

The satellite is supported by three pre-recorded presentations:

  • A view of the HIV pipeline: Kundai Chinyenze, IAVI.
  • A view of the TB pipeline: Katrin Eichelberg, NIAID (NIH)
  • An overview of HIV and TB R&D funding: Mike Frick, TAG.

Visit the Satellite page to find out more.

Wednesday 03 February, 18:45 – 19:45 (UTC) channel 2

Vaccines: What HIV R&D did for COVID-19.

The COVID-19 pandemic is showing that a rapid response to a public health challenge of planetary scale is possible. This remarkable response is benefitting from existing technologies, capacity and capabilities, and especially from previous work on HIV prevention, treatment and cure research.

The satellite will present the findings of report commissioned by the Global HIV Vaccine Enterprise on how investment in HIV vaccine Research and Development (R&D) has enabled the rapid advancement of COVID-19 vaccine R&D.

This event will bring together researchers, clinicians, community members, industry and regulators and aim to raise the visibility and contribution of HIV vaccine R&D to the COVID-19 response to the global community and ensure that innovation arising from COVID-19 vaccine research benefits future HIV vaccines research.

WP Twitter Auto Publish Powered By : XYZScripts.com